Authorized purpose: Quantitative characterization and longitudinal tracking of user-detected solid pulmonary nodules at least 6 mm on chest CT.
Clinical role
User-assisted semi-automatic nodule segmentation, measurement, and longitudinal comparison; results are informational, not diagnostic, and the clinician reviews and corrects the segmentation against the original images.
Images and patients
CT/CTA · Chest and lungs
Key limitation
Keep in mind: The device is not intended to diagnose disease or replace physician evaluation. Image noise and artifacts may reduce performance; use is not intended for idiopathic pulmonary fibrosis or extensive granulomatous disease or scans outside compatibility. Follow-up should use consistent CT parameters, and the clinician must verify or manually correct segmentation. Calculator and guideline outputs depend on user-entered information.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Quantitative characterization and longitudinal tracking of user-detected solid pulmonary nodules at least 6 mm on chest CT.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest and lungs Input: Non-contrast chest CT scans with user-selected or user-segmented solid pulmonary nodules at least 6 mm; DICOM input, received as de-identified scans through a modality or PACS.
Who uses it?Intended users: Radiologists and pulmonologists; certified medical specialists trained and experienced in reviewing and reporting chest CT.
What does the software produce?Output: Quantitative nodule average, long-axis, short-axis, and effective diameters, volume, mean/minimum/maximum HU, volume-doubling time, 2D/3D segmented views, Lung-RADS calculation, Brock Score risk calculation, and Fleischner-guideline-based reporting support.
What is its most important limitation?Key limitation: The device is not intended to diagnose disease or replace physician evaluation. Image noise and artifacts may reduce performance; use is not intended for idiopathic pulmonary fibrosis or extensive granulomatous disease or scans outside compatibility. Follow-up should use consistent CT parameters, and the clinician must verify or manually correct segmentation. Calculator and guideline outputs depend on user-entered information.
Clinical takeaway. Clinical role: Quantitative characterization and longitudinal tracking of user-detected solid pulmonary nodules at least 6 mm on chest CT.
Evidence takeaway. Evidence from the reviewed source record: FDA standalone clinical performance testing included 216 solid nodules from 118 chest CT scans of 104 subjects, with ground truth established by three expert radiologists. Median absolute normalized errors were 14.3% for short-axis diameter (95% CI 13.95%-16.67%), 11.1% for long-axis diameter (9.52%-12.50%), and 20.7% for volume (17.29%-22.41%). The packet describes these as quantitative measurement results against the reference standard and does not report diagnostic sensitivity or specificity.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Quantitative characterization and longitudinal tracking of user-detected solid pulmonary nodules at least 6 mm on chest CT.
User-assisted semi-automatic nodule segmentation, measurement, and longitudinal comparison; results are informational, not diagnostic, and the clinician reviews and corrects the segmentation against the original images.
Non-contrast chest CT scans with user-selected or user-segmented solid pulmonary nodules at least 6 mm; DICOM input, received as de-identified scans through a modality or PACS.
The device is not intended to diagnose disease or replace physician evaluation. Image noise and artifacts may reduce performance; use is not intended for idiopathic pulmonary fibrosis or extensive granulomatous disease or scans outside compatibility. Follow-up should use consistent CT parameters, and the clinician must verify or manually correct segmentation. Calculator and guideline outputs depend on user-entered information.
FDA standalone clinical performance testing included 216 solid nodules from 118 chest CT scans of 104 subjects, with ground truth established by three expert radiologists. Median absolute normalized errors were 14.3% for short-axis diameter (95% CI 13.95%-16.67%), 11.1% for long-axis diameter (9.52%-12.50%), and 20.7% for volume (17.29%-22.41%). The packet describes these as quantitative measurement results against the reference standard and does not report diagnostic sensitivity or specificity.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA standalone clinical performance testing included 216 solid nodules from 118 chest CT scans of 104 subjects, with ground truth established by three expert radiologists. Median absolute normalized errors were 14.3% for short-axis diameter (95% CI 13.95%-16.67%), 11.1% for long-axis diameter (9.52%-12.50%), and 20.7% for volume (17.29%-22.41%). The packet describes these as quantitative measurement results against the reference standard and does not report diagnostic sensitivity or specificity.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
qCT LN Quant regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K240740
Samplen=104
IndependenceIndependence not established
K240740
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240740. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Non-contrast chest CT scans with user-selected or user-segmented solid pulmonary nodules at least 6 mm; DICOM input, received as de-identified scans through a modality or PACS.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: A cloud module receives de-identified DICOM scans from a modality or PACS and returns results to the same destination. PACS mode uses a secondary-capture series with segmentation for PACS supporting GSPS output; web mode displays overlays in the Qure web application. Exact local interfaces and versions are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes qCT LN Quant as consisting of a cloud module that receives de-identified scans from a DICOM modality or PACS and returns results there, with a web-based mode showing segmentation on Qure's web application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "qCT LN Quant consists of a cloud module that can interacts with DICOM modality or the user’s picture archiving and communication system (PACS) to receive de-identified scans and returns the results to the same destination" … "Web-based mode: On Qure’s web application where the segmentation is overlaid on top of the original scan.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Quantitative nodule average, long-axis, short-axis, and effective diameters, volume, mean/minimum/maximum HU, volume-doubling time, 2D/3D segmented views, Lung-RADS calculation, Brock Score risk calculation, and Fleischner-guideline-based reporting support.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes qCT LN Quant as consisting of a cloud module that receives de-identified scans from a DICOM modality or PACS and returns results there, with a web-based mode showing segmentation on Qure's web application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "qCT LN Quant consists of a cloud module that can interacts with DICOM modality or the user’s picture archiving and communication system (PACS) to receive de-identified scans and returns the results to the same destination" … "Web-based mode: On Qure’s web application where the segmentation is overlaid on top of the original scan.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
A cloud module receives de-identified DICOM scans from a modality or PACS and returns results to the same destination. PACS mode uses a secondary-capture series with segmentation for PACS supporting GSPS output; web mode displays overlays in the Qure web application. Exact local interfaces and versions are not established.
Qure.ai's documentation FAQ says data is sent over HTTPS (TLS 1.2 or higher), stored encrypted at rest with AES-256-GCM, backed up with restore tests twice a year, and that Qure maintains an ISO 27001 certification with periodic surveillance audits. It also says hospitals anonymize PHI before sending data. The certificate itself was not read and no date or scope is given.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Qure.ai's vulnerability disclosure programme states that it covers all Qure.ai commercial products, including cloud-hosted products and Qure.ai-operated infrastructure, and commits to handling every report promptly and transparently with an acknowledgement and tracking reference within 2 business days.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Qure.ai generally and does not scope these commitments to any specific product release; exact-release scope is not established. The programme is an intake and response-handling commitment; it makes no uptime, drift or continuous-monitoring claims.
ACR AI Central provides an exact-submission model card for qCT LN Quant; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K240740 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
Authorized purpose: AI-Rad Companion Pulmonary is image-processing software that provides quantitative and qualitative analysis from previously acquired CT DICOM images to support radiologists and physicians in evaluating and assessing lung disease. It segments and measures lungs, lobes, parenchyma, and solid or sub-solid nodules, identifies areas above or below specified Hounsfield-value thresholds, supports an external Lung CAD interface, associates nodules with lobes, and compares current nodules with known priors. Valid input is DICOM imaging of adult patients; the FDA summary identifies software version VA40.
Modality
CT/CTA
Anatomy
Adult lungs, lung lobes, pulmonary parenchyma, and solid or sub-solid lung nodules
AI-Rad Companion (Pulmonary) is image processing software that provides quantitative and qualitative analysis from previously acquired Computed Tomography DICOM images to support radiologists and physicians from emergency medicine, specialty care, urgent care, and general practice in the evaluation and assessment of disease of the lungs. It provides the following functionality: Segmentation and measurements of complete lung and lung lobes Identification of areas with lower Hounsfield values in comparison to a predefined threshold for complete lung and lung lobes Providing an interface to external Medical Device syngo.CT Lung CAD Segmentation and measurements of solid lung nodules. Dedication of found lung nodules to corresponding lung lobe. Correlation of segmented lung nodules of current scan with known priors and quantitative assessment of changes of the correlated data. Identification of areas with elevated Hounsfield values, where areas with elevated versus high opacities are distinguished. The software has been validated for data from Siemens Healthineers (filtered back projection and iterative reconstruction),GE Healthcare (filtered back projection reconstruction), and Philips (filtered back projection reconstruction).Only DI COM images of adult patients are considered to be valid input.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.